KR100829407B1 - 클라미디아 감염을 치료 및 진단하기 위한 조성물 및 이를 포함하는 약제학적 조성물 및 진단 키트 - Google Patents

클라미디아 감염을 치료 및 진단하기 위한 조성물 및 이를 포함하는 약제학적 조성물 및 진단 키트 Download PDF

Info

Publication number
KR100829407B1
KR100829407B1 KR1020017007165A KR20017007165A KR100829407B1 KR 100829407 B1 KR100829407 B1 KR 100829407B1 KR 1020017007165 A KR1020017007165 A KR 1020017007165A KR 20017007165 A KR20017007165 A KR 20017007165A KR 100829407 B1 KR100829407 B1 KR 100829407B1
Authority
KR
South Korea
Prior art keywords
seq
chlamydia
chlamydia trachomatis
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020017007165A
Other languages
English (en)
Korean (ko)
Other versions
KR20010101152A (ko
Inventor
프롭스트페터
바티아아야이
스케이키야시르에이더블유
플링스티븐피
옌쉬안
스트롬버그에리카진
Original Assignee
코릭사 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/208,277 external-priority patent/US6166177A/en
Priority claimed from US09/288,594 external-priority patent/US6447779B1/en
Priority claimed from US09/410,568 external-priority patent/US6555115B1/en
Application filed by 코릭사 코포레이션 filed Critical 코릭사 코포레이션
Publication of KR20010101152A publication Critical patent/KR20010101152A/ko
Application granted granted Critical
Publication of KR100829407B1 publication Critical patent/KR100829407B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020017007165A 1998-12-08 1999-12-08 클라미디아 감염을 치료 및 진단하기 위한 조성물 및 이를 포함하는 약제학적 조성물 및 진단 키트 Expired - Fee Related KR100829407B1 (ko)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US09/208,277 US6166177A (en) 1998-12-08 1998-12-08 Compounds and methods for the treatment and diagnosis of chlamydial infection
US09/208,277 1998-12-08
US09/288,594 US6447779B1 (en) 1998-12-08 1999-04-08 Compounds for the diagnosis of Chlamydial infection
US09/288,594 1999-04-08
US09/410,568 1999-10-01
US09/410,568 US6555115B1 (en) 1998-12-08 1999-10-01 Compounds and methods for treatment and diagnosis of chlamydial infection
US42657199A 1999-10-22 1999-10-22
US09/426,571 1999-10-22

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020077022107A Division KR20070108263A (ko) 1998-12-08 1999-12-08 클라미디아 감염을 치료 및 진단하기 위한 조성물 및 이를포함하는 약제학적 조성물 및 진단 키트

Publications (2)

Publication Number Publication Date
KR20010101152A KR20010101152A (ko) 2001-11-14
KR100829407B1 true KR100829407B1 (ko) 2008-05-15

Family

ID=27498718

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020017007165A Expired - Fee Related KR100829407B1 (ko) 1998-12-08 1999-12-08 클라미디아 감염을 치료 및 진단하기 위한 조성물 및 이를 포함하는 약제학적 조성물 및 진단 키트
KR1020107027275A Abandoned KR20100132086A (ko) 1998-12-08 1999-12-08 클라미디아 감염을 치료 및 진단하기 위한 조성물 및 이를 포함하는 약제학적 조성물 및 진단 키트
KR1020077022107A Ceased KR20070108263A (ko) 1998-12-08 1999-12-08 클라미디아 감염을 치료 및 진단하기 위한 조성물 및 이를포함하는 약제학적 조성물 및 진단 키트
KR1020097016159A Ceased KR20090088972A (ko) 1998-12-08 1999-12-08 클라미디아 감염을 치료 및 진단하기 위한 조성물 및 이를 포함하는 약제학적 조성물 및 진단 키트

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020107027275A Abandoned KR20100132086A (ko) 1998-12-08 1999-12-08 클라미디아 감염을 치료 및 진단하기 위한 조성물 및 이를 포함하는 약제학적 조성물 및 진단 키트
KR1020077022107A Ceased KR20070108263A (ko) 1998-12-08 1999-12-08 클라미디아 감염을 치료 및 진단하기 위한 조성물 및 이를포함하는 약제학적 조성물 및 진단 키트
KR1020097016159A Ceased KR20090088972A (ko) 1998-12-08 1999-12-08 클라미디아 감염을 치료 및 진단하기 위한 조성물 및 이를 포함하는 약제학적 조성물 및 진단 키트

Country Status (18)

Country Link
EP (5) EP2277892A3 (enExample)
JP (2) JP2002531129A (enExample)
KR (4) KR100829407B1 (enExample)
CN (1) CN100365120C (enExample)
AT (1) ATE469222T1 (enExample)
AU (2) AU769293B2 (enExample)
BR (1) BR9916020A (enExample)
CA (2) CA2354232A1 (enExample)
DE (1) DE69942426D1 (enExample)
ES (1) ES2346832T3 (enExample)
HK (1) HK1044020B (enExample)
HU (1) HUP0400719A3 (enExample)
IL (5) IL143531A0 (enExample)
MX (1) MXPA01005813A (enExample)
NO (2) NO20012812L (enExample)
NZ (1) NZ512246A (enExample)
TR (1) TR200102500T2 (enExample)
WO (1) WO2000034483A2 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7459524B1 (en) 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
WO1999053948A1 (en) * 1998-04-20 1999-10-28 THE STATE OF OREGON, acting by and through THE STATE BOARD OF HIGHER EDUCATION, on behalf of OREGON STATE UNIVERSITY Chlamydia proteins and their uses
AU5365999A (en) 1998-08-20 2000-03-14 Connaught Laboratories Limited Nucleic acid molecules encoding pomp91a protein of (chlamydia)
AU5366099A (en) 1998-08-20 2000-03-14 Connaught Laboratories Limited Nucleic acid molecules encoding inclusion membrane protein of (chlamydia)
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
US6649370B1 (en) 1998-10-28 2003-11-18 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6607730B1 (en) 1998-11-02 2003-08-19 Aventis Pasteur Limited/Aventis Pasteur Limitee Chlamydia antigens and corresponding DNA fragments and uses thereof
WO2000032784A1 (en) 1998-12-01 2000-06-08 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US6565856B1 (en) 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6447779B1 (en) 1998-12-08 2002-09-10 Corixa Corporation Compounds for the diagnosis of Chlamydial infection
US20020061848A1 (en) * 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
US6448234B1 (en) 1998-12-08 2002-09-10 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6432916B1 (en) 1998-12-08 2002-08-13 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6555115B1 (en) 1998-12-08 2003-04-29 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
EP2277892A3 (en) 1998-12-08 2011-04-27 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US7297341B1 (en) 1998-12-23 2007-11-20 Sanofi Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6808713B1 (en) 1998-12-28 2004-10-26 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
NZ512448A (en) 1998-12-28 2004-01-30 Aventis Pasteur Chlamydia antigens and corresponding DNA fragments and uses thereof
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
DE60041042D1 (de) 1999-03-12 2009-01-22 Aventis Pasteur Chlamydia antigene und deren korrespondierende dna fragmente und verwendungen davon
DE60036698T2 (de) 1999-05-03 2008-07-24 Sanofi Pasteur Ltd., Toronto Chlamydia-antigene und entsprechende dna-fragmente und deren verwendungen
AU783547B2 (en) 1999-09-20 2005-11-10 Sanofi Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
JP4864264B2 (ja) 1999-12-22 2012-02-01 サノフィ、パストゥール、リミテッド クラミジア抗原および対応するｄｎａ断片ならびにその使用
ATE389020T1 (de) 2000-04-21 2008-03-15 Corixa Corp Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen
US6919187B2 (en) 2000-04-21 2005-07-19 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
DE60125350T2 (de) 2000-05-08 2007-07-12 Sanofi Pasteur Ltd., Toronto Chlamydia-antigene, entsprechende dns-fragmente und ihre verwendungen
ATE440861T1 (de) * 2000-07-03 2009-09-15 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia pneumoniae
US7537772B1 (en) * 2000-10-02 2009-05-26 Emergent Product Development Gaithersburg Inc. Chlamydia protein, gene sequence and the uses thereof
US7731980B2 (en) 2000-10-02 2010-06-08 Emergent Product Development Gaithersburg Inc. Chlamydia PMP proteins, gene sequences and uses thereof
GB2378056A (en) * 2001-07-27 2003-01-29 William Dixon Electrical connection device
ES2312649T3 (es) 2001-12-12 2009-03-01 Novartis Vaccines And Diagnostics S.R.L. Inmunizacion frente a chlamydia trachomatis.
GB0203403D0 (en) 2002-02-13 2002-04-03 Chiron Spa Chlamydia cytotoxic-T cell epitopes
JP2004261017A (ja) * 2003-02-27 2004-09-24 Arkray Inc クラミジア・トラコマティスの検出方法およびそのためのキット
CA2602637A1 (en) * 2005-03-31 2006-10-05 Glaxosmithkline Biologicals Sa Vaccines against chlamydial infection
US9259463B2 (en) * 2006-01-16 2016-02-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Chlamydia vaccine
AU2007304199A1 (en) * 2006-10-04 2008-04-10 Corixa Corporation Vaccines against Chlamydial infection
US20100310593A1 (en) * 2007-06-14 2010-12-09 Emergent Product Development Gaithersburg Inc. Vaccines Against Chlamydia Infection
US8568732B2 (en) 2009-03-06 2013-10-29 Novartis Ag Chlamydia antigens
US9458513B2 (en) 2010-03-23 2016-10-04 Wako Pure Chemical Industries, Ltd. Primer and probe for detecting chlamydia trachomatis, and method for detecting chlamydia trachomatis using same
JP7146732B2 (ja) * 2016-07-13 2022-10-04 オハイオ ステート イノベーション ファウンデーション 宿主抗原提示並びに宿主抗腫瘍及び抗病原体免疫を最適化するためのプラットフォーム及び方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999028475A2 (en) * 1997-11-28 1999-06-10 Genset Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4489710A (en) 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
US4429008B1 (en) 1981-12-10 1995-05-16 Univ California Thiol reactive liposomes
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
JPS59116229A (ja) 1982-12-24 1984-07-05 Teijin Ltd 細胞毒性複合体を活性成分とする癌治療用剤およびその製造法
US4673562A (en) 1983-08-19 1987-06-16 The Children's Medical Center Corporation Bisamide bisthiol compounds useful for making technetium radiodiagnostic renal agents
US4873088A (en) 1983-09-06 1989-10-10 Liposome Technology, Inc. Liposome drug delivery method and composition
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4918164A (en) 1987-09-10 1990-04-17 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US4735792A (en) 1987-04-28 1988-04-05 The United States Of America As Represented By The United States Department Of Energy Radioiodinated maleimides and use as agents for radiolabeling antibodies
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP1645635A3 (en) 1989-08-18 2010-07-07 Oxford Biomedica (UK) Limited Replication defective recombinant retroviruses expressing a palliative
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
EP0761231B1 (en) 1992-06-25 2000-01-12 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
US5359681A (en) 1993-01-11 1994-10-25 University Of Washington Fiber optic sensor and methods and apparatus relating thereto
US5840297A (en) * 1993-03-19 1998-11-24 Johns Hopkins University Vaccine comprising anti-idiotypic antibody to chlamydia GLXA and process
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP0772619B2 (en) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
EP2045261A1 (en) * 1994-09-20 2009-04-08 Hitachi Chemical Co., Ltd. Chlamydia pneumoniae antigenic polypeptides
AU3876795A (en) * 1994-11-17 1996-06-17 Maxim Pharmaceuticals, Inc. Immunogens for stimulating mucosal immunity
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
EP0832282A1 (en) 1995-06-02 1998-04-01 Incyte Pharmaceuticals, Inc. IMPROVED METHOD FOR OBTAINING FULL-LENGTH cDNA SEQUENCES
WO1997024447A1 (en) 1996-01-02 1997-07-10 Chiron Corporation Immunostimulation mediated by gene-modified dendritic cells
EP0915978B1 (en) * 1996-07-12 2005-12-14 University of Manitoba Dna immunization against chlamydia infection
US6464979B1 (en) * 1996-09-12 2002-10-15 Aventis Pasteur Limited Chlamydial vaccines and methods of preparation thereof
BR9814878A (pt) 1997-11-21 2000-10-03 Genset Sa Sequência genÈmica e polipeptìdeos de chlamydia pneumoniae, fragmentos dos mesmos e usos dos mesmos, em particular para o diagnóstico, a prevenção e o tratamento de infecção
AU5297399A (en) * 1998-08-20 2000-03-14 Aventis Pasteur Limited (chlamydia) antigens and corresponding dna fragments and uses thereof
EP1133572A4 (en) 1998-11-12 2005-06-15 Univ California GENOMIC SEQUENCE OF CHLAMYDIA PNEUMONIAE
US6565856B1 (en) 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
EP2277892A3 (en) 1998-12-08 2011-04-27 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
DE60036698T2 (de) 1999-05-03 2008-07-24 Sanofi Pasteur Ltd., Toronto Chlamydia-antigene und entsprechende dna-fragmente und deren verwendungen
AU783547B2 (en) 1999-09-20 2005-11-10 Sanofi Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
CA2388461C (en) * 1999-09-28 2013-06-11 Infectio Diagnostic (I.D.I.) Inc. Highly conserved genes and their use to generate probes and primers for the detection of microorganisms
JP4864264B2 (ja) 1999-12-22 2012-02-01 サノフィ、パストゥール、リミテッド クラミジア抗原および対応するｄｎａ断片ならびにその使用
ATE389020T1 (de) 2000-04-21 2008-03-15 Corixa Corp Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen
DE60125350T2 (de) 2000-05-08 2007-07-12 Sanofi Pasteur Ltd., Toronto Chlamydia-antigene, entsprechende dns-fragmente und ihre verwendungen
ATE440861T1 (de) 2000-07-03 2009-09-15 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia pneumoniae
US9103184B2 (en) 2013-03-08 2015-08-11 Tejas Research & Engineering, Llc Inflow control valve
WO2016023894A1 (en) 2014-08-11 2016-02-18 U3 Pharma Gmbh Human anti-fgfr4 antibody

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999028475A2 (en) * 1997-11-28 1999-06-10 Genset Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCIENCE, Vol. 282, 23 October 1998, pages 754-759. *

Also Published As

Publication number Publication date
EP2223935A2 (en) 2010-09-01
CN1333832A (zh) 2002-01-30
IL143531A0 (en) 2002-04-21
HK1044020A1 (zh) 2002-10-04
NZ512246A (en) 2003-12-19
AU1935800A (en) 2000-06-26
CA2746535A1 (en) 2000-06-15
ES2346832T3 (es) 2010-10-20
IL209116A0 (en) 2011-01-31
KR20010101152A (ko) 2001-11-14
CA2354232A1 (en) 2000-06-15
ATE469222T1 (de) 2010-06-15
EP2277892A2 (en) 2011-01-26
NO20012812L (no) 2001-08-02
AU2004201702B2 (en) 2007-07-05
NO20012812D0 (no) 2001-06-07
EP2218733A1 (en) 2010-08-18
HUP0400719A2 (hu) 2004-07-28
EP1144642A2 (en) 2001-10-17
DE69942426D1 (de) 2010-07-08
EP2223935A3 (en) 2010-11-24
AU2004201702A1 (en) 2004-05-20
AU769293B2 (en) 2004-01-22
KR20100132086A (ko) 2010-12-16
KR20070108263A (ko) 2007-11-08
IL209114A0 (en) 2011-01-31
WO2000034483A9 (en) 2001-07-05
EP2277893A3 (en) 2011-03-30
NO20101293L (no) 2001-08-02
PL363147A1 (en) 2004-11-15
KR20090088972A (ko) 2009-08-20
EP1144642B1 (en) 2010-05-26
HK1044020B (zh) 2008-10-31
JP2002531129A (ja) 2002-09-24
IL209113A0 (en) 2011-01-31
EP2277893A2 (en) 2011-01-26
WO2000034483A2 (en) 2000-06-15
EP2277892A3 (en) 2011-04-27
HUP0400719A3 (en) 2010-08-30
IL209115A0 (en) 2011-01-31
JP2011036258A (ja) 2011-02-24
BR9916020A (pt) 2002-01-22
CN100365120C (zh) 2008-01-30
MXPA01005813A (es) 2002-05-06
TR200102500T2 (tr) 2002-03-21
WO2000034483A3 (en) 2001-11-01

Similar Documents

Publication Publication Date Title
KR100829407B1 (ko) 클라미디아 감염을 치료 및 진단하기 위한 조성물 및 이를 포함하는 약제학적 조성물 및 진단 키트
US6565856B1 (en) Compounds and methods for treatment and diagnosis of chlamydial infection
CZ2001200A3 (en) Herbicidal agents containing substituted phenylsulfonyl ureas compounds for controlling weed in rice, process of their preparation and use
US6448234B1 (en) Compounds and methods for treatment and diagnosis of chlamydial infection
PL209107B1 (pl) Kompozycje do zastosowania w leczeniu i diagnozowaniu infekcji Chlamydia
US6432916B1 (en) Compounds and methods for treatment and diagnosis of chlamydial infection
CN101219215A (zh) 用于治疗及诊断衣原体感染的化合物和方法
CA2408199A1 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
US6555115B1 (en) Compounds and methods for treatment and diagnosis of chlamydial infection
US20080213264A1 (en) Compounds and methods for treatment and diagnosis of chlamydial infection
HK1146285A (en) Compounds and methods for treatment and diagnosis of chlamydial infection
HK1146286A (en) Compounds and methods for treatment and diagnosis of chlamydial infection
HK1067381B (en) Compounds and methods for treatment and diagnosis of chlamydial infection

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

A107 Divisional application of patent
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A17-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20110428

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20120508

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20120508